T. Rowe Price Investment Management, Inc. Ascendis Pharma A/S Transaction History
T. Rowe Price Investment Management, Inc.
- $164 Billion
- Q3 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 2,666,618 shares of ASND stock, worth $545 Million. This represents 0.32% of its overall portfolio holdings.
Number of Shares
2,666,618
Previous 3,583,546
25.59%
Holding current value
$545 Million
Previous $619 Million
14.29%
% of portfolio
0.32%
Previous 0.39%
Shares
13 transactions
Others Institutions Holding ASND
# of Institutions
316Shares Held
65.1MCall Options Held
476KPut Options Held
142K-
Ra Capital Management, L.P. Boston, MA10.3MShares$2.1 Billion35.1% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.26MShares$1.08 Billion4.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.11MShares$1.04 Billion13.88% of portfolio
-
Janus Henderson Group PLC London, X04.32MShares$884 Million0.41% of portfolio
-
Lombard Odier Asset Management (Europe) LTD London, X04.27MShares$873 Million0.89% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $11.4B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...